摘要
骨质疏松是一种常见的全身性骨代谢疾病,主要表现为骨密度与骨量的下降,从而导致继发性骨折。目前,随着其发病率不断增高,骨质疏松已经成为一个世界范围的健康问题和当前医学的研究热点。骨吸收抑制剂主要作用于破骨细胞,通过抑制破骨细胞分化成熟,减少骨吸收;骨形成促进剂主要作用于成骨细胞,激活其骨形成功能,并且有重建骨组织的效应;骨矿化物是防治骨质疏松的基础药物,包括钙剂和维生素D;解偶联剂种类较为单一,代表药物为雷尼酸锶。主要对以上四大类抗骨质疏松药物的研究进展进行介绍。
Osteoporosis (OP) is a systemic bone metabolism disease characterized by a systemic impairment of bone mass, strength,and microarchitecture,which will be result in increasing the propensity of fragility fractures . In recent years, OP becomes a worldwide health problem and a hotspot in medical research due to its increasing incidence . Anti-resorptive drugs inhibit osteoclast differentiation and maturation in order to reduce bone resorption, Bone-anabolic drugs promote the bone for-mation function of osteoblast and reconstruct bone tissue , Bone mineralization-acceleration drugs are the basic material for pre-vention and treatment of osteoporosis , including calcium and vitamin D , Strontium ranelate is the representative drug of un - coupling agents . In this paper,the current progress of osteoporosis treatments were reviewed including these proposed drugs .
作者
贾文斌
刘超
邹燕
JIA Wenbin;LIU Chao;ZOU Yan(Department of Pharmacy , Qingdao First Sanatorium of Navy Military , Qingdao 266071 ,China;Department of Organic Chemistry,School of Pharmacy,Second Military Medical University , Shanghai200433 , China)
出处
《药学实践杂志》
CAS
2017年第6期490-494,542,共6页
Journal of Pharmaceutical Practice
关键词
骨质疏松
药物
治疗
骨吸收抑制剂
骨形成促进剂
骨矿化促进剂
osteoporosis
drugs
therapy
anti-resorptive drugs
bone-anabolic drugs
bone mineralization-acceleration drugs